Thermal and X-ray analysis of racemic bupivacaine hydrochloride by A. Sykuła-Zając et al.
Thermal and X-ray analysis of racemic bupivacaine
hydrochloride
A. Sykuła-Zaja˛c • E. Łodyga-Chrus´cin´ska •
B. Pałecz • R. E. Dinnebier • U. J. Griesser •
V. Niederwanger
Received: 25 August 2010 / Accepted: 23 February 2011 / Published online: 26 March 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract An amide-type local anesthetic drug, bupiva-
caine hydrochloride (BupiHCl), in the form of racemate is
listed in the European and American pharmacopoeias and
continues to be used in medicine. Thermal and X-ray anal-
ysis of commercial BupiHCl monohydrate was performed by
differential scanning calorimetry with thermogravimetry,
hot stage microscopy, and X-ray diffraction. Endothermic
dehydration occurs at the temperature range of 73–130 C
for DSC–TG 111 (Setaram) and at 83–150 C for DSC 404
(Netzsch). Both curves at 2 and 10 C min-1 clearly reflect
phase transformation of anhydrous Form I into II before
reaching the melting point. A well-defined exothermic phase
transition of BupiHCl was detected at a lower heating rate.
Temperature-resolved X-ray diffraction in conjunction with
DSC led to determining a similarity between the obtained
thermal events. Microscopic investigation also confirmed
the above-mentioned transformations.
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Introduction
Bupivacaine hydrochloride (BupiHCl) is a long-acting
local anesthetic widely used in clinical practice. This
water-soluble compound is listed in the European and
American pharmacopoeias. Bupivacaine is a xylidine
derivative which belongs to the family of 1-alkyl-20,60-
pipecoloxylidides (Fig. 1) which is promising in terms of
reversibly blocking potential action in sensory nerves by
means of a receptor-independent mechanism [1]. The
administration of local anesthetics in the form of a free
base or in the ionized state can induce analgesia either by
general physicochemical disturbance of the neuron myelin
sheath or by closing ionic sodium channels in the neuronal
membrane [2].
The drug is still clinically available as a racemate which
consists of ‘‘left-handed’’ S(-)- and ‘‘right-handed’’ R(?)-
[3] enantiomers at a ratio of 50:50 [4]. S(-)-bupivacaine,
which is called levobupivacaine [5, 6] produces a neuronal
blockade of a longer duration and is less toxic to the central
nervous and cardiovascular systems [7, 8]. Therefore, more
and more studies concerning levobupivacaine have been
reported in the literature [9–13]. Nevertheless, racemic
mixtures of bupivacaine are still in common use in
medicine.
Commercial ‘as is’ bupivacaine hydrochloride was
determined by Giron et al. [14] to be a monohydrate which
transforms into an anhydrous form upon heating. They also
showed the potential existence of solvates with ethanol,
isopropanol, and ethyl acetate. BupiHCl in the form of
A. Sykuła-Zaja˛c (&)  E. Łodyga-Chrus´cin´ska
Institute of General Food Chemistry, Faculty of Biotechnology
and Food Sciences, Technical University of Lodz,
Stefanowskiego 4/10, 90-924 Lodz, Poland
e-mail: anna.sykula-zajac@p.lodz.pl
B. Pałecz
Department of Physical Chemistry, Faculty of Physics
and Chemistry, University of Lodz, Pomorska 149/153,
90-236 Lodz, Poland
R. E. Dinnebier
Max Planck Institute for Solid State Research, Heisenbergstrasse
1, 70569 Stuttgart, Germany
U. J. Griesser  V. Niederwanger
Department of Pharmaceutical Technology,
Institute of Pharmacy, Leopold Franzens University Innsbruck,
Innrain 52, 6020 Innsbruck, Austria
123
J Therm Anal Calorim (2011) 105:1031–1036
DOI 10.1007/s10973-011-1425-9
monohydrate is not very stable thermally and dehydrates at
above 60 C.
Statistical analyses show that only about 10% of race-
mates are conglomerates, while the vast majority of them
are racemic compounds. Bupivacaine belongs to that 10%
group of conglomerate compounds, which offers the pos-
sibility for optical resolution by preferential crystallization
[15].
Moreover, it is known that BupiHCl is polymorphic
[16]. Temperature-resolved X-ray experiments performed
by Giron et al. demonstrated the existence of two anhy-
drous forms. The forms were detected by heating and
cooling processes fluctuating between 100 and 170 C
[14]. Furthermore, four new forms of BupiHCl were dis-
covered by utilization of the ‘‘Basic Screen’’ polymorph
screening protocol and were differentiated using instru-
mental methods such as differential scanning calorimetry
(DSC), X-ray powder diffraction (XRPD), and polarized
light microscopy (PLM).
The present thermal and X-ray analysis was performed
on the currently most popular racemic mixture of BupiHCl.
The objective of this study was to carefully investigate the
thermal behavior of the widely administered drug using
thermal analytical techniques (DSC, TGA, and thermomi-
croscopy) and X-ray diffractometry to identify any rela-
tionships between the obtained results.
Experimental
Material
Bupivacaine HCl was purchased as a monohydrate from
Sigma-Aldrich, Inc., St. Louis, United States of America
(99% purity). The commercial substance occurs in the form
of white crystal powder.
Thermal investigations
Thermal investigations were performed by DSC 404
(Netzsch, Selb) using the TA Universal Analysis software.
A Sartorius balance was used to weigh a 4.4 ± 0.0005 mg
sample into an aluminum pan (Perkin-Elmer) with a per-
forated cover. Dry argon was used as the purge gas (purge:
75 mL min-1), and the system was calibrated with indium
(purity 99.999%, melting point 156.6 C, heat of fusion
28.60 J g-1), tin (melting point 232.70 C, heat of fusion
60.40 J g-1), and quartz (melting point 573.50 C, heat of
fusion 8.40 J g-1). A heating rate of 10 C min-1 was
routinely used.
A differential scanning calorimeter coupled with a
Setaram DSC–TG 111 thermobalance was also used in
thermal investigations. A 6.21 ± 0.0005 mg sample was
weighed into an aluminum pan using a Mettler AE20
balance. Dry nitrogen was used as the purge gas (purge:
30–40 mL min-1), and the system was calibrated with
indium (purity 99.999%, melting point 156.6 C, heat of
fusion 28.45 J g-1), lead (melting point 327.50 C, heat of
fusion 23.22 J g-1), zinc (melting point 419.47 C, heat of
fusion 103.79 J g-1), and tin (melting point 231.93 C,
heat of fusion 60.60 J g-1). A heating rate of 2 C min-1
was routinely used.
The thermal behavior of the solid-state forms was
examined with a Reichert Thermovar polarization
microscope (Reichert, Vienna, A) equipped with a Kofler
hot stage (Reichert, Vienna, A). Microphotographs were
produced with 200 lm scale bars.
Temperature-resolved XRPD investigations
Structural investigations were performed at the Angs-
tro¨mquelle Karlsruhe (ANKA) synchrotron in Karlsruhe, at
the Max Planck Institute. The source of radiation at the
beamline was a 1.5 T bending magnet, which offered
X-ray energies between 6 and 20 keV. The first optical
device in the path of X-rays was a rhodium-coated silicon
mirror. The mirror focused the beam in the vertical direc-
tion. A double silicon (111) crystal monochromator was
used to select the wavelength of 1.238879 A˚ and focus the
beam in the horizontal direction [17]. The measurement
was done in Debye–Scherrer mode with the sample spun to
improve counting statistics. A MarCCD 165 detector was
used for the detection of scattered peak intensities. A
modified Leister 700 hot air tool with a tubular nozzle was
used as a heating device. The temperature was controlled
by a Eurotherm 2461 self-optimizing temperature control-
ler. The hot air blower was set vertically several millime-
ters below the capillary. The pin was fitted into a Huber
goniometer head and aligned. The measurements were











Fig. 1 Molecular formula of bupivacaine hydrochloride (C18H28N2
OHCl, H2O, 342.99 g mol-1)
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dynamic mode of heating rate close to 1.5 C min-1. The
whole time of measurement totalled 3 h. Treatment of the
X-ray powder patterns obtained was done with Powder3D
[18].
Results and discussions
Thermal investigations of racemic BupiHCl
Thermal investigations using DSC
The thermal curves obtained from two calorimeters, one of
which was equipped with a thermobalance, are presented in
Fig. 2. The first, standard measurement of the commercial
mixture was done with a DSC 404 calorimeter using
only the DSC method at 10 C min-1 at the Max Planck
Institute in Stuttgart. Double heating without TG mea-
surement or cooling of the BupiHCl sample was performed
(gray solid and dotted lines, respectively). The DSC curve
of the first heating is similar to the curve obtained by Giron
et al. [14]. The Netzsch Thermal Analysis software was
used to determine the temperatures of the peaks. The cor-
responding endothermic peaks at 116.60 and 133.40 C
(Eendo = 191.8 mW) probably present a two-stage dehy-
dration process. The temperature range of the dehydration
process is rather wide; therefore, a deconvolution operation
was performed. The deconvolution of coupled peaks
was done with the PeakSeparation (PeakSep) software
(Netzsch). The onset and endpoint of the first peak are at
111.60 and 124.00 C, respectively. The second step of the
dehydration process of BupiHCl starts at 113.50 C and
ends at 142 C. The percentage area of the corresponding
peaks was calculated. The percentage values of the areas
are ca. 21 and 79%, respectively. Hence, one can suppose
that the release of water molecules during dehydration
takes place at the ratio of 1 to 4. Probably two-stage
dehydration was observed, because the decomposition of
hydrates (including solvates) is supposed to occur by pro-
gressive evacuation of the solvent through interlayer planes
or channels controlled by an overall diffusion process [19].
Exothermic phase transition was observed at above
150 C (after the dehydration process) on the DSC curve at
10 C min-1. The transition starts and ends at 170.80 and
210 C, respectively (see inset in Fig. 2). The phase tran-
sition (Eexo = -5.2 mW) probably corresponds to the
change of the metastable form (Form I) of the anhydrate
existing in the range 150–170 C into the stable form
(Form II) present in the temperature range of 210–240 C.
Form II is monotropically related to Form I as it was
observed in the corresponding temperature range for exo-
thermic transition on the first and second heating curves
shown in Fig. 2 (dotted line). Form II exists up to the
decomposition process of the sample at *240 C. Above
this temperature, the BupiHCl sample undergoes decom-
position as shown by the second heating curve. A second
heating does not reveal any thermal event throughout the
temperature range. Therefore, a second heating was not
applied in subsequent measurements.
Thermal investigations using DSC–TG 111
BupiHCl was reexamined using the DSC–TG method at
2 C min-1 at a temperature range of 20–203 C to
investigate it using another calorimeter equipped with a
thermobalance and at a lower heating rate. Measurement at
higher temperatures was not performed due to the risk of
contamination of the thermobalance.
The DSC curve at 2 C min-1 reveals the suggested two-
stage dehydration process and a well-defined exothermic
phase transition (Fig. 2). Both curves at 2 and 10 C min-1
clearly and consistently reflect phase transformation of the
anhydrous substance before the melting point. Due to a
slower heating rate, the corresponding temperatures of
109.97 and 117.178 C (Eendo = 167.2 mW) in the dehy-
dration and phase transition of the anhydrous form
(178.16 C, Eexo = -4.7 mW) begin earlier than observed
on the DSC curve obtained with the Netzsch instrument. The
anhydrous Form I exists between 130 and 163 C and the
anhydrous Form II from 194 C to the decomposition of the
sample.
The use of a thermobalance in the analysis enabled
estimating the loss of mass during thermal dehydration. No
two-stage dehydration process was observed on the TG
curve, as opposed to both DSC curves. It is probably due to
the gradual release of water molecules from the racemic
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Fig. 2 Thermal curves of racemic bupivacaine hydrochloride at
2 C min-1, first heating (DSC–TG 111), and at 10 C min-1, first
and second heating (DSC 404); the inset shows the range of
exothermic transition
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variation was 0.277 mg. Furthermore, the ratio of water
molecules in BupiHCl equals 1:1.186 and confirms that the
commercial substance has the monohydrate form.
Thermomicroscopic investigations
The thermomicroscopic behavior of racemic BupiHCl
crystals using hot stage microscopy at a heating rate of
5–10 C min-1 (HTM) is given in Fig. 3. BupiHCl mono-
hydrate crystals at 25 C occur as small and large particles
not exceeding 200 lm (Fig. 3a).
Parallel cracks form in crystals under the influence of
temperature (Fig. 3b, see yellow arrow), but at the same
time the initial shape of the crystals is maintained. The
cracks are the result of dehydration of the substance. The
thermal process probably happens because of gradual
release of water from interlayer planes or channels. Reor-
ganization begins in the inner part of each particle without
loss of crystallinity [19, 20]. Heated crystals undergo
chemical degradation, which was confirmed by the dark-
ening of crystals. This phenomenon was also noticed by
Kuhnert-Brandsta¨tter [21] during analysis of BupiHCl
monohydrate. The tested substance transformed into
anhydrous form at 115 C with a simultaneous darkening
of the crystals.
After the dehydration process, the appearance of new
crystalline forms (Fig. 3c and d) was detected in the tem-
perature range of 135–190 C. While heating, they exhibit
further growth and nucleation. The newly obtained crys-
talline forms (Fig. 3d) occur as long, narrow, and blunt-
ended crystals. ‘‘Nucleation and growth’’ models assume
that transitions start at a particular site (generally, crystal
defects for polymorphic transitions and particle surface for
dehydrations) and continue by a progressive propagation of
the reaction interface [19]. The expected polymorphic
transition between the anhydrous Forms I and II proceeds
by nucleation and growth.
Temperature-resolved X-ray and DSC investigations
The thermal behavior of BupiHCl was compared with DSC
results and temperature-resolved X-ray diffraction data.
The X-ray patterns of BupiHCl monohydrate were identi-
fied using the ANKA synchrotron. The patterns in the 3D
project were analyzed against the DSC curves obtained
with a Setaram DSC–TG 111 calorimeter (Fig. 4). The
XRD patterns and the DSC curve were both recorded at a
very similar heating rate.
Endothermic dehydration and exothermic phase transi-
tion measured at corresponding temperatures observed on
the DSC curve also appeared in the collection of 3D-plot
X-ray patterns. The existence of an exothermic event in the
X-ray pattern set has not been reported so far. The above-
mentioned processes are shifted in terms of temperature. In
addition, Fig. 5 shows approximately the corresponding
X-ray patterns of exothermic phase transition for anhy-
drous BupiHCl. The data present the temperature values
from the DSC curve (DSC–TG 111) and the counting time
at each temperature for corresponding X-ray patterns.
Moreover, in Fig. 5 the temperature values of exothermic
transition occurring in the X-ray pattern set were added as
red arrows. The temperatures, which demonstrate an onset
(163 C), peak point (178.16 C), and endpoint (194 C) of
exothermic phase transition, do not overlap with the X-ray
Fig. 3 Microphotographs of
racemic bupivacaine
hydrochloride monohydrate at
a 25 C, b 110 C, c 135 C,
and d 190 C
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patterns exactly. Probably Forms I and II exist at the same
temperature range simultaneously.
Conclusions
The commercial form of racemic BupiHCl, being a
monohydrate, transforms into the anhydrous form which
undergoes further transformation (Form I ? Form II)
during heating. All of the methods used, i.e., DSC with
thermogravimetry, hot stage microscopy, and X-ray dif-
fraction confirm the presence of endothermic dehydration
and exothermic phase transition of BupiHCl.
No two-stage dehydration process was observed on the
TG curve, in contrast to both DSC curves. It is probably
due to the gradual release of water molecules from
BupiHCl racemic crystals. During dehydration, mass var-
iation was 0.277 mg. The ratio of water molecules in Bu-
piHCl equals 1:1.186, which confirms the claim that the
commercial substance occurs in monohydrate form.
Phase transition is detected after BupiHCl dehydration.
Furthermore, both DSC curves obtained from different
calorimeters at the heating rates of 2 and 10 C min-1
clearly reflect the phase transformation of the anhydrous
substance before the melting point.
DSC and X-ray diffraction are two powerful tools in
studying the thermal behavior of racemic BupiHCl. DSC
alone cannot perfectly detect phase transitions of very low
enthalpies. On the other hand, X-ray diffraction is unable to
provide thermodynamic information relating to phase
transition. In the course of using the conventional method,
more problems will arise from the thermal history of the
sample. Thus, the best solution is to apply both techniques.
In our case, the comparison of evidence of exothermic
phase transition seen both in X-ray diffraction patterns and
the DSC curve was possible at almost the same heating rate
(1.5–2 C min-1). The respective temperatures reflected in
the DSC curve (DSC–TG 111), which demonstrate the
onset (163 C), peak point (178.16 C), and endpoint
(194 C) of the exothermic phase transition, do not overlap
with the X-ray patterns exactly. Probably Forms I and II
exist at the same temperature range simultaneously.
Thermomicroscopic analysis shows parallel cracks
resulting from the dehydration of the substance. Further-
more, upon heating crystals undergo chemical degradation,
confirmed by their darkening. Subsequently, new anhy-
drous crystalline forms are obtained in the temperature
range of 135–190 C. Thermomicroscopic analysis con-
firms the thermal transformation of BupiHCl racemate.
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Fig. 4 3D X-ray patterns and the DSC curve at the temperature range
of 35–203 C for BupiHCl monohydrate showing both the endother-
mic process of dehydration and exothermic phase transition. The data
show the exact temperature values of DSC thermal events and the























Fig. 5 3D X-ray patterns showing exothermic phase transition
approximately [the corresponding temperatures occurring on the
DSC curve (DSC–TG 111) and temperature values with counting time
at each temperature for respective X-ray patterns)
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